{"id":273483,"date":"2018-10-04T16:49:01","date_gmt":"2018-10-04T16:49:01","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=273483"},"modified":"2018-10-04T16:49:01","modified_gmt":"2018-10-04T16:49:01","slug":"creative-biolabs-initiates-innovative-native-antibody-discovery-platform-for-highaffinity-native-antibodies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/creative-biolabs-initiates-innovative-native-antibody-discovery-platform-for-highaffinity-native-antibodies_273483.html","title":{"rendered":"Creative Biolabs Initiates Innovative Native\u2122 Antibody Discovery Platform for High-affinity Native Antibodies"},"content":{"rendered":"
Recently Creative Biolabs, an industry leader in discovery and optimization of antibodies, announced the launching of advanced Native\u2122 Antibody Discovery Platform to develop native monoclonal antibodies by using antigen-specific B lymphocytes cytometry technology.<\/div>\n

Recently Creative Biolabs, an industry leader in discovery and optimization of antibodies, announced the launching of advanced Native™ Antibody Discovery Platform to develop native monoclonal antibodies by using antigen-specific B lymphocytes cytometry technology.<\/p>\n

Creative Biolabs has established the exclusively reliable and accurate Native™ Antibody Discovery Platform in order to provide a tailor-made service combine with rapid analysis procedures and clearly report, which allows us to isolate single antigen-specific plasma cells to retrieve native antibodies with extremely high in vivo specificity and affinity.<\/p>\n

Several limitations have been observed in current in vitro<\/em> antibody display methods. On one hand, these methods cannot provide naturally paired heavy chain and light chain of antibodies, which could potentially lead to the generation of antibody molecules that have suboptimal solubility or other biophysical characteristics. As a result, antibodies derived from these technologies most likely do not represent the naturally cognate heavy and light chains. On the other hand, the antibody derived from these methods generally have the moderate affinity to the targets and require further affinity maturation before used as potential therapeutics. Thereby, phage libraries are restricted to about 1010<\/sup> to 1011<\/sup> total diversity by the efficiency of bacterial transformation as well as by the practical limit of phage particle density of about 1013<\/sup>\/mL.<\/p>\n

“In order to overcome the limitations of traditional in vitro<\/em> antibody display methods, Creative Biolabs has proudly developed the exclusive technical platform for better antibody discovery<\/a>. With this method, we’re able to isolate single antigen-specific plasma cells and retrieve native antibodies efficiently. Moreover, this new technology allows us to select a large number of antibody candidates at once and it only takes 2-3 weeks post-immunization. It should be considered by far the most efficient way in developing native monoclonal antibodies from humans, rabbits, rats, mice, chicken and other species such as camelids, sheep, monkeys, dogs, and even cows. For initiating native antibody development, single B cells need to be isolated and identified. Based on the principles used, the existing techniques can be classified into two groups, the one based on cell physical properties and the other one based on cellular biological characteristics,” Said Dr. John of Creative Biolabs.<\/p>\n

Creative Biolabs<\/strong> is continuing to optimizing its  platform and provides reliable, rapid and cost-effective targeted Native™ Antibody Discovery Platform based on the native paired heavy chain and light chain combine with high specificity and stability in vivo<\/em> and a large pool of antibody candidates. Also, there are diverse species available to fit researchers’ needs.<\/p>\n

 <\/strong><\/p>\n

About Creative Biolabs<\/strong><\/p>\n

As a pioneer and the undisputed global leader in antibody discovery and manufacturing, Creative Biolabs<\/strong> is programming native monoclonal antibodies for both academic and industrial use. The advancement of the company’s antibody production<\/a> platforms and its highly professional scientists allows it to provide efficient high throughput and super-sensitivity services, including monoclonal antibody production using phage display<\/a> technology for bulk scale antibody manufacturing and so on.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative Biolabs
Contact Person:<\/strong> Bella Smith
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1-631-619-7922
Address:<\/strong>45-1 Ramsey Road
City:<\/strong> Shirley
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.creative-biolabs.com\/<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Recently Creative Biolabs, an industry leader in discovery and optimization of antibodies, announced the launching of advanced Native\u2122 Antibody Discovery Platform to develop native monoclonal antibodies by using antigen-specific B lymphocytes cytometry technology. Recently Creative Biolabs, an industry leader in … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-273483","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/273483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=273483"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/273483\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=273483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=273483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=273483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}